FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202330513> ?p ?o ?g. }

• W3202330513 endingPage "766" @default.
• W3202330513 startingPage "755" @default.
• W3202330513 abstract "Background Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes and normal or near-normal kidney function. Whether this effect persists in patients with chronic kidney disease with and without type 2 diabetes is unknown. We assessed the effects of dapagliflozin on albuminuria in patients with chronic kidney disease with and without type 2 diabetes in the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Methods DAPA-CKD was a multicentre, double-blind, placebo-controlled, randomised trial done at 386 sites in 21 countries. Patients were eligible for the trial if they had chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR) between 25 mL/min per 1·73 m2 and 75 mL/min per 1·73 m2 and a urinary albumin-to-creatinine ratio (UACR) between 200 mg/g and 5000 mg/g (22·6 to 565·6 mg/mmol). Participants were randomly assigned to dapagliflozin 10 mg (AstraZeneca; Gothenburg, Sweden) once daily or matching placebo, in accordance with the sequestered, fixed randomisation schedule, using balanced blocks to ensure an approximate 1:1 ratio. Change in albuminuria was a pre-specified exploratory outcome of DAPA-CKD. Regression in UACR stage, defined as a transition from macroalbuminuria (≥300 mg/g) to microalbuminuria or normoalbuminuria (<300 mg/g), and progression in UACR stage, defined as a transition from less than 3000 mg/g to 3000 mg/g or greater, were additional discrete endpoints. The trial is registered with ClinicalTrials.gov, NCT03036150. Findings Between Feb 2, 2017, and April 3, 2020, 4304 patients were recruited and randomly assigned to either dapagliflozin (n=2152) or placebo (n=2152). Median UACR was 949 mg/g (IQR 477 to 1885). Overall, compared with placebo, dapagliflozin reduced geometric mean UACR by 29·3% (95% CI –33·1 to –25·2; p<0·0001); relative to placebo, treatment with dapagliflozin resulted in a geometric mean percentage change of −35·1% (95% CI −39·4 to −30·6; p<0·0001) in patients with type 2 diabetes and −14·8% (−22·9 to −5·9; p=0·0016) in patients without type 2 diabetes over the follow-up visits (pinteraction<0·0001) Among 3860 patients with UACR of 300 mg/g or greater at baseline, dapagliflozin increased the likelihood of regression in UACR stage (hazard ratio 1·81, 95% CI 1·60 to 2·05). Among 3820 patients with UACR less than 3000 mg/g at baseline, dapagliflozin decreased the risk of progression in UACR stage (0·41, 0·32 to 0·52). Larger reductions in UACR at day 14 during dapagliflozin treatment were significantly associated with attenuated eGFR decline during subsequent follow-up (β per log unit UACR change –3·06, 95% CI –5·20 to –0·90; p=0·0056). Interpretation In patients with chronic kidney disease with and without type 2 diabetes, dapagliflozin significantly reduced albuminuria, with a larger relative reduction in patients with type 2 diabetes. The similar effects of dapagliflozin on clinical outcomes in patients with or without type 2 diabetes, but different effects on UACR, suggest that part of the protective effect of dapagliflozin in patients with chronic kidney disease might be mediated through pathways unrelated to reduction in albuminuria. Funding AstraZeneca." @default.
• W3202330513 created "2021-10-11" @default.
• W3202330513 creator A5008309890 @default.
• W3202330513 creator A5012551917 @default.
• W3202330513 creator A5016452405 @default.
• W3202330513 creator A5018701033 @default.
• W3202330513 creator A5031624913 @default.
• W3202330513 creator A5034939991 @default.
• W3202330513 creator A5041913215 @default.
• W3202330513 creator A5048450888 @default.
• W3202330513 creator A5060560730 @default.
• W3202330513 creator A5069865054 @default.
• W3202330513 creator A5078418468 @default.
• W3202330513 creator A5084032669 @default.
• W3202330513 creator A5085592050 @default.
• W3202330513 creator A5085677017 @default.
• W3202330513 date "2021-11-01" @default.
• W3202330513 modified "2023-10-15" @default.
• W3202330513 title "Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial" @default.
• W3202330513 cites W1992719998 @default.
• W3202330513 cites W2017268330 @default.
• W3202330513 cites W2032442361 @default.
• W3202330513 cites W2111663222 @default.
• W3202330513 cites W2112457187 @default.
• W3202330513 cites W2150392479 @default.
• W3202330513 cites W2152413054 @default.
• W3202330513 cites W2492672367 @default.
• W3202330513 cites W2537726188 @default.
• W3202330513 cites W2595201361 @default.
• W3202330513 cites W2600135630 @default.
• W3202330513 cites W2769932926 @default.
• W3202330513 cites W2807732548 @default.
• W3202330513 cites W2884817413 @default.
• W3202330513 cites W2908535040 @default.
• W3202330513 cites W2939203716 @default.
• W3202330513 cites W2939222610 @default.
• W3202330513 cites W2940024069 @default.
• W3202330513 cites W3005350465 @default.
• W3202330513 cites W3035468154 @default.
• W3202330513 cites W3047823383 @default.
• W3202330513 cites W3083452684 @default.
• W3202330513 cites W3088173406 @default.
• W3202330513 cites W3089612515 @default.
• W3202330513 cites W3112405194 @default.
• W3202330513 cites W3116741673 @default.
• W3202330513 cites W3153542350 @default.
• W3202330513 cites W3201867211 @default.
• W3202330513 doi "https://doi.org/10.1016/s2213-8587(21)00243-6" @default.
• W3202330513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34619106" @default.
• W3202330513 hasPublicationYear "2021" @default.
• W3202330513 type Work @default.
• W3202330513 sameAs 3202330513 @default.
• W3202330513 citedByCount "59" @default.
• W3202330513 countsByYear W32023305132021 @default.
• W3202330513 countsByYear W32023305132022 @default.
• W3202330513 countsByYear W32023305132023 @default.
• W3202330513 crossrefType "journal-article" @default.
• W3202330513 hasAuthorship W3202330513A5008309890 @default.
• W3202330513 hasAuthorship W3202330513A5012551917 @default.
• W3202330513 hasAuthorship W3202330513A5016452405 @default.
• W3202330513 hasAuthorship W3202330513A5018701033 @default.
• W3202330513 hasAuthorship W3202330513A5031624913 @default.
• W3202330513 hasAuthorship W3202330513A5034939991 @default.
• W3202330513 hasAuthorship W3202330513A5041913215 @default.
• W3202330513 hasAuthorship W3202330513A5048450888 @default.
• W3202330513 hasAuthorship W3202330513A5060560730 @default.
• W3202330513 hasAuthorship W3202330513A5069865054 @default.
• W3202330513 hasAuthorship W3202330513A5078418468 @default.
• W3202330513 hasAuthorship W3202330513A5084032669 @default.
• W3202330513 hasAuthorship W3202330513A5085592050 @default.
• W3202330513 hasAuthorship W3202330513A5085677017 @default.
• W3202330513 hasBestOaLocation W32023305132 @default.
• W3202330513 hasConcept C126322002 @default.
• W3202330513 hasConcept C126894567 @default.
• W3202330513 hasConcept C134018914 @default.
• W3202330513 hasConcept C142724271 @default.
• W3202330513 hasConcept C159641895 @default.
• W3202330513 hasConcept C204787440 @default.
• W3202330513 hasConcept C27081682 @default.
• W3202330513 hasConcept C2776174234 @default.
• W3202330513 hasConcept C2777180221 @default.
• W3202330513 hasConcept C2777422806 @default.
• W3202330513 hasConcept C2778653478 @default.
• W3202330513 hasConcept C2780306776 @default.
• W3202330513 hasConcept C2781203188 @default.
• W3202330513 hasConcept C555293320 @default.
• W3202330513 hasConcept C71924100 @default.
• W3202330513 hasConceptScore W3202330513C126322002 @default.
• W3202330513 hasConceptScore W3202330513C126894567 @default.
• W3202330513 hasConceptScore W3202330513C134018914 @default.
• W3202330513 hasConceptScore W3202330513C142724271 @default.
• W3202330513 hasConceptScore W3202330513C159641895 @default.
• W3202330513 hasConceptScore W3202330513C204787440 @default.
• W3202330513 hasConceptScore W3202330513C27081682 @default.
• W3202330513 hasConceptScore W3202330513C2776174234 @default.
• W3202330513 hasConceptScore W3202330513C2777180221 @default.
• W3202330513 hasConceptScore W3202330513C2777422806 @default.
• W3202330513 hasConceptScore W3202330513C2778653478 @default.

• next